TABLE 1.
Patient characteristics
| MRI group | US group | MRI and US group | All patients | |
|---|---|---|---|---|
| Number of patients | 226 | 401 | 107 | 520 |
| Age at initial visit (years) | ||||
| Mean | 51.28 | 51.60 | 49.88 | 51.82 |
| SD | 10.96 | 11.49 | 10.76 | 11.38 |
| Median | 52.00 | 51.00 | 50.00 | 51.00 |
| Min | 25.00 | 21.00 | 26.00 | 21.00 |
| Max | 77.00 | 78.00 | 77.00 | 78.00 |
| N.D. | 2 | 2 | 1 | 3 |
| Central grade, N (%) | ||||
| 1 | 4 (1.77) | 7 (1.75) | 2 (1.87) | 9 (1.73) |
| 2 | 95 (42.04) | 181 (45.14) | 47 (43.93) | 229 (44.04) |
| 3 | 125 (55.31) | 211 (52.62) | 57 (53.27) | 279 (53.65) |
| N.D. | 2 (0.88) | 2 (0.50) | 1 (0.93) | 3 (0.58) |
| Clinical baseline characteristics, N (%) | ||||
| cT | ||||
| 1 | 96 (42.48) | 178 (44.39) | 42 (39.25) | 232 (44.62) |
| 2 | 121 (53.54) | 198 (49.38) | 59 (55.14) | 260 (50.00) |
| 3 | 8 (3.54) | 23 (5.74) | 6 (5.61) | 25 (4.81) |
| 4 | 1 (0.44) | 2 (0.50) | — | 3 (0.58) |
| cN | ||||
| 0 | 150 (66.37) | 290 (72.32) | 72 (67.29) | 368 (70.77) |
| 1 | 66 (29.20) | 99 (24.69) | 32 (29.91) | 133 (25.58) |
| 2 | 9 (3.98) | 11 (2.74) | 2 (1.87) | 18 (3.46) |
| 3 | 1 (0.44) | 1 (0.25) | 1 (0.93) | 1 (0.19) |
| Menopausal status | ||||
| Premenopausal | 106 (46.90) | 198 (49.38) | 53 (49.53) | 251 (48.27) |
| Postmenopausal | 107 (47.35) | 178 (44.39) | 45 (42.06) | 240 (46.15) |
| Unknown/unclear | 13 (5.75) | 25 (6.23) | 9 (8.41) | 29 (5.58) |
| BC subtype and therapy, N (%) | ||||
| HR+/HER2+ | 96 (42.48) | 258 (64.34) | 66 (61.68) | 288 (55.38) |
| pCR rate, N (%) | 34 (35.42) | 78 (30.23) | 23 (34.85) | 89 (30.90) |
| Ki‐67 response rate, N (%) | 58 (60.42) | 145 (56.20) | 42 (63.64) | 161 (55.90) |
| T‐DM1 | 33 (14.60) | 84 (20.95) | 23 (21.50) | 94 (18.08) |
| T‐DM1+ET | 30 (13.27) | 86 (21.45) | 20 (18.69) | 96 (18.46) |
| Trastuzumab+ET | 33 (14.60) | 88 (21.95) | 23 (21.50) | 98 (18.85) |
| HR−/HER2− | 87 (38.50) | 93 (23.19) | 25 (23.36) | 155 (29.81) |
| pCR rate, N (%) | 29 (33.33) | 30 (32.26) | 5 (20.00) | 54 (34.84) |
| Ki‐67 response rate, N (%) | 39 (44.83) | 42 (45.16) | 13 (52.00) | 68 (43.87) |
| nab‐paclitaxel+gemcitabine | 50 (22.12) | 56 (13.97) | 17 (15.89) | 89 (17.12) |
| nab‐paclitaxel+carboplatin | 37 (16.37) | 37 (9.23) | 8 (7.48) | 66 (12.69) |
| HR‐/HER2+ | 43 (19.03) | 50 (12.47) | 16 (14.96) | 77 (14.81) |
| pCR rate, N (%) | 20 (46.51) | 29 (58.00) | 9 (56.25) | 40 (51.95) |
| Ki‐67 response rate, N (%) | 13 (30.23) | 20 (40.00) | 4 (25.00) | 29 (37.66) |
| Trastuzumab+pertuzumab | 32 (14.16) | 35 (8.73) | 12 (11.21) | 55 (10.58) |
| Trastuzumab+pertuzumab+paclitaxel | 11 (4.87) | 15 (3.74) | 4 (3.73) | 22 (4.23) |